AmassMap the current landscape for oral GLP-1 agonists in obesity — what's approved, what's in trials, and who holds patents.AmassMake the case for and against KRAS G12D as a drug target: biology, what's been tried clinically, and failures.AmassWhat happened to semaglutide since first approval — indication expansions, label changes, safety signals, and literature.

Amass connects your assistant to six curated biomedical corpora: BioMedCore (43M+ records: peer-reviewed publications from PubMed/PMC and conference abstracts from society meetings), TrialCore (1.2M+ clinical trials from ClinicalTrials.gov and the WHO ICTRP), DrugCore (22K+ harmonized drugs/molecules covering modality, clinical stage, structure, synonyms, and the gene targets each drug acts on; ChEMBL-linked), RegulatoryCore (7K+ unified FDA + EMA marketing authorizations with source documents such as labels, reviews, SmPCs, and EPARs), GeneCore (43K+ harmonized human genes with a target-intelligence layer covering druggability, DepMap essentiality, ChEMBL target class, clinical-precedent tractability, curated safety liabilities, and gnomAD constraint), and PatentCore (preview, life-science patents with full-text search, CPC/IPC classifications, assignees/inventors, and patent families). Users can search and retrieve full records with filters that beat open-web retrieval, and follow cross-links across corpora back to each underlying source.

აპი

Amass